B-cell therapy let lupus haemolytic anaemia come off steroids sooner

Design

Multicentre retrospective comparative cohort

Population

70 patients with systemic lupus-associated warm autoimmune haemolytic anaemia

Primary outcome

6-month overall response rate

Effect

Overall response 89.7% vs 85.7% (not significant); lower 1-month steroid dose with B-cell therapy

Warm autoimmune haemolytic anaemia complicating systemic lupus is usually treated with high-dose glucocorticoids and conventional immunosuppression. This retrospective cohort of 70 patients compared that approach with B-cell-targeted therapy — rituximab, belimumab or telitacicept — started within 14 days.

Response rates were similar: 6-month overall response was 89.7% with B-cell-targeted therapy versus 85.7% with conventional therapy, with no significant difference. The differences favouring B-cell therapy were a numerically higher complete-response rate (61.5% vs 42.9%), a more stable 12-month response, and — significantly — a lower prednisone-equivalent dose at one month (40 vs 50 mg/day). All seven telitacicept-treated patients responded.

The practical interest is steroid sparing: comparable control with less glucocorticoid exposure is worth having in a disease where steroid toxicity accumulates. The cohort is small and retrospective, with the B-cell group younger and more active, so these are exploratory signals that need prospective confirmation.

• Retrospective cohort of 70 patients with first-episode lupus-associated warm haemolytic anaemia.
• 6-month overall response 89.7% with B-cell-targeted therapy vs 85.7% conventional (not significant).
• Complete response was numerically higher with B-cell therapy (61.5% vs 42.9%).
• Prednisone-equivalent dose at one month was lower with B-cell therapy (40 vs 50 mg/day).
• Exploratory and retrospective, with the B-cell group younger and more active at baseline.

Why it matters

It raises the prospect of controlling a serious lupus complication while cutting glucocorticoid exposure, the main driver of long-term damage.

Don't overread it

Small, retrospective and confounded by baseline differences; the response and steroid-sparing signals need prospective trials.

The statistics, in plain English

Similar response rates with a wide confidence interval mean no proven superiority; the earlier steroid taper is the firmer finding, though baseline differences between groups could flatter the B-cell arm.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.